AbbVie stock weekly forecast: Recent rally steadies as resistance looms at $291.36

AbbVie stock weekly forecast: Recent rally steadies as resistance looms at $291.36
AbbVie gains 0.76% over the week

Shares of AbbVie Inc. (ABBV) are trading near $287, holding steady after a quiet week where the recovery remained intact. As the rally shows signs of becoming stretched, investors are watching whether bullish momentum can persist into next week.

ABBV price prediction
24H -0.33%
$296.72
48H -0.15%
$297.27
7D -0.09%
$297.43
1M 3.51%
$308.16
3M 11.91%
$333.18
6M 4.92%
$312.36
12M 26.86%
$377.68
Current price: $297.71 2.62 0.89%
Real-time Data 11:25
Daily range 293.73 Arrow from to Icon 297.20
Weekly range 289.80 Arrow from to Icon 300.31
Loading...

Highlights

  • Shares of AbbVie climbed to $287.48, advancing over the past 7 days and maintaining a strong uptrend.
  • The price remains in a bullish long-term structure with indicators showing robust momentum, though overbought conditions are approaching.
  • Key support is at $276.39, resistance at $291.36, with a projected trading range of $280.78 to $294.17 in the coming week.

Oncology and immunology updates boost sentiment as clinical results emerge

AbbVie is set to present new and updated data from its solid tumor research portfolio at the European Society for Medical Oncology Congress in Madrid, representing its largest presence to date, according to PR Newswire. The company also announced new clinical trial data showing its investigational Crohn’s disease therapy outperformed existing monotherapies in a Phase 2a study, and highlighted 20 new scientific abstracts from its inflammatory bowel disease portfolio at the United European Gastroenterology Week (sources: GuruFocus, GuruFocus). These developments reinforce ABBV’s ongoing focus on oncology and immunology research.

AbbVie Inc. asset chart
AbbVie Inc. price dynamics. Source: TradingView.

Uptrend persists as technical signals approach overbought thresholds

On the daily chart, AbbVie maintains a strong upward trend, with a sustained move higher and a firm trend character. Both the MACD and ADX signal continued buyer control, while the RSI is approaching overbought territory at 67.26, suggesting momentum remains robust but nearing stretched levels. Nearest support is at $276.39, with the Ichimoku Kijun at $274.58 also acting as a practical backstop, while resistance stands at $291.36. Volatility over the past 7 days has been moderate at 5.42%, which supports the ongoing trending move.

Breakout risk intensifies as bullish bias holds for the coming week

Over the coming trading week, the expected range is $280.78 to $294.17. There is a 75% probability of an increase and a 25% probability of a decrease. The base case is that the stock continues trending between current levels and resistance at $291.36. A break above $291.36 would open the way for further upside, while a move below support at $276.39 could shift momentum to the downside.

Viktoras Karapetjanc, expert at Traders Union, sees AbbVie shares maintaining strong momentum this week, backed by robust technicals and encouraging news flow. The stock’s steady trend above support at $276.39, along with MACD and ADX confirming buyer control, points to sustained optimism. Recent positive news from AbbVie’s oncology and immunology research, including new solid tumor data and Crohn’s disease trial results, strengthens the growth narrative and fuels sentiment. With resistance at $291.36 in sight and the RSI nearing overbought at 67.26, the setup still favors further upside within the $280.78–$294.17 range. "Investors should remain constructive as innovation drives performance and the technical structure favors further growth in the coming week."

In a recent review, analysts highlighted AbbVie's sustained technical momentum and positive clinical results as key drivers underpinning a bullish outlook for the stock. With new data releases and major scientific presentations broadening AbbVie's research credentials, investors should monitor the $291.36 resistance level for signs of a potential breakout in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.